Literature DB >> 22169585

Heart-type fatty acid binding protein and the diagnosis of acute coronary syndrome in the ED.

Yonathan Freund1, Camille Chenevier-Gobeaux, François Leumani, Yann-Erick Claessens, Jean-Christophe Allo, Benoit Doumenc, Claudine Cosson, Pascale Bonnet, Bruno Riou, Patrick Ray.   

Abstract

BACKGROUND: In combination with cardiac troponin, heart-type fatty acid binding protein (h-FABP)-a biomarker of myocardial necrosis-offers the possibility of rapidly eliminating the diagnosis of acute myocardial infarction (AMI).
OBJECTIVE: The main objective of this study was to assess the incremental value of h-FABP to cardiac troponin for a rapid elimination of AMI, according to the pretest probability (PTP) of AMI.
METHODS: In consecutive patients presenting to emergency departments (ED) with chest pain less than 6 hours suggestive of AMI, h-FABP levels were measured, blinded to the ED physicians, who were asked to quote the PTP of AMI. The discharge diagnosis was adjudicated by 2 independent experts, blind to the h-FABP level.
RESULTS: Three hundred seventeen patients (mean age of 57 years) were included in whom 149 had (47%) low, 117 (37%) moderate, and 51 (16%) high PTP. The final diagnosis was AMI in 45 patients (14%), including 16 STEMIs (5%). The negative predictive value for diagnostic elimination of AMI of an h-FABP less than 3 μg/L, combined with a negative cTnI was not higher than that of cardiac troponin I (cTnI) alone (96% [95% confidence interval, 93%-98%] vs 95% [93%-98%]), regardless of the PTP). Even in the low-PTP group, we did not demonstrate a significant improvement in negative predictive value with the addition of h-FABP, compare with that of cTnI alone (100% [97%-100%] vs 99% [96%-100%]).
CONCLUSION: In triage of patients with chest pain, use of h-FABP does not provide useful additional information to cTnI for excluding the diagnosis of ST-elevation myocardial infarction and non-ST-elevation myocardial infarction diagnosis, whatever the PTP.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22169585     DOI: 10.1016/j.ajem.2011.10.001

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  5 in total

1.  Heart-Type Fatty Acid-Binding Protein, in Early Detection of Acute Myocardial Infarction: Comparison with CK-MB, Troponin I and Myoglobin.

Authors:  Anand K Pyati; Basavaraj B Devaranavadagi; Sanjeev L Sajjannar; Shashikant V Nikam; Mohd Shannawaz; Satish Patil
Journal:  Indian J Clin Biochem       Date:  2016-01-13

2.  Value of heart-type fatty acid-binding protein (H-FABP) for emergency department patients with suspected acute coronary syndrome.

Authors:  Karakus Yilmaz Banu; Ozüçelik Doğaç Niyazi; Cevik Erdem; Doğan Hatice Dpekçi Afşin; Uzun Ozlem; Celik Yasemin; Ipekci Afsin
Journal:  Afr Health Sci       Date:  2014-09       Impact factor: 0.927

Review 3.  Circulating microRNAs as novel biomarkers for the early diagnosis of acute coronary syndrome.

Authors:  J C Deddens; J M Colijn; M I F J Oerlemans; G Pasterkamp; S A Chamuleau; P A Doevendans; J P G Sluijter
Journal:  J Cardiovasc Transl Res       Date:  2013-07-30       Impact factor: 4.132

4.  Comparison of a qualitative measurement of heart-type fatty acid-binding protein with other cardiac markers as an early diagnostic marker in the diagnosis of non-ST-segment elevation myocardial infarction.

Authors:  Demet Menekşe Gerede; Sadi Güleç; Mustafa Kiliçkap; Cansin Tulunay Kaya; Veysel Kutay Vurgun; Özgür Ulaş Özcan; Hüseyin Göksülük; Çetin Erol
Journal:  Cardiovasc J Afr       Date:  2015-07-14       Impact factor: 1.167

5.  Plasma Macrophage Migration Inhibitor Factor Is Elevated in Response to Myocardial Ischemia.

Authors:  Fenling Fan; Lu Fang; Xiao-Lei Moore; Xuegang Xie; Xiao-Jun Du; David A White; Jessica O'Brien; Helen Thomson; Jun Wang; Hans G Schneider; Andris Ellims; Thomas W Barber; Anthony M Dart
Journal:  J Am Heart Assoc       Date:  2016-06-30       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.